These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 31829492)
1. Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism. Winzker M; Friese A; Koch U; Janning P; Ziegler S; Waldmann H Angew Chem Int Ed Engl; 2020 Mar; 59(14):5595-5601. PubMed ID: 31829492 [TBL] [Abstract][Full Text] [Related]
2. Structure-based development of PDEδ inhibitors. Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847 [TBL] [Abstract][Full Text] [Related]
3. Membrane protein transport in photoreceptors: the function of PDEδ: the Proctor lecture. Baehr W Invest Ophthalmol Vis Sci; 2014 Dec; 55(12):8653-66. PubMed ID: 25550383 [TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer. Cheng J; Li Y; Wang X; Dong G; Sheng C J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594 [TBL] [Abstract][Full Text] [Related]
5. Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ. Ozdemir ES; Jang H; Gursoy A; Keskin O; Nussinov R J Phys Chem B; 2018 Aug; 122(30):7503-7513. PubMed ID: 29961325 [TBL] [Abstract][Full Text] [Related]
6. The interplay between RPGR, PDEδ and Arl2/3 regulate the ciliary targeting of farnesylated cargo. Wätzlich D; Vetter I; Gotthardt K; Miertzschke M; Chen YX; Wittinghofer A; Ismail S EMBO Rep; 2013 May; 14(5):465-72. PubMed ID: 23559067 [TBL] [Abstract][Full Text] [Related]
7. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780 [TBL] [Abstract][Full Text] [Related]
8. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer. Leung EL; Luo LX; Li Y; Liu ZQ; Li LL; Shi DF; Xie Y; Huang M; Lu LL; Duan FG; Huang JM; Fan XX; Yuan ZW; Ding J; Yao XJ; Ward DC; Liu L Int J Cancer; 2019 Sep; 145(5):1334-1345. PubMed ID: 30786019 [TBL] [Abstract][Full Text] [Related]
9. Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity. Lee J; Lee HJ; Lee Y; Lim B; Gam J; Oh DC; Lee J J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1656-1666. PubMed ID: 35695156 [TBL] [Abstract][Full Text] [Related]
10. Identification of pyrazolopyridazinones as PDEδ inhibitors. Papke B; Murarka S; Vogel HA; Martín-Gago P; Kovacevic M; Truxius DC; Fansa EK; Ismail S; Zimmermann G; Heinelt K; Schultz-Fademrecht C; Al Saabi A; Baumann M; Nussbaumer P; Wittinghofer A; Waldmann H; Bastiaens PI Nat Commun; 2016 Apr; 7():11360. PubMed ID: 27094677 [TBL] [Abstract][Full Text] [Related]
11. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Zimmermann G; Papke B; Ismail S; Vartak N; Chandra A; Hoffmann M; Hahn SA; Triola G; Wittinghofer A; Bastiaens PI; Waldmann H Nature; 2013 May; 497(7451):638-42. PubMed ID: 23698361 [TBL] [Abstract][Full Text] [Related]
12. Assay and functional properties of PrBP(PDEdelta), a prenyl-binding protein interacting with multiple partners. Zhang H; Hosier S; Terew JM; Zhang K; Cote RH; Baehr W Methods Enzymol; 2005; 403():42-56. PubMed ID: 16473576 [TBL] [Abstract][Full Text] [Related]
13. Photoreceptor cGMP phosphodiesterase delta subunit (PDEdelta) functions as a prenyl-binding protein. Zhang H; Liu XH; Zhang K; Chen CK; Frederick JM; Prestwich GD; Baehr W J Biol Chem; 2004 Jan; 279(1):407-13. PubMed ID: 14561760 [TBL] [Abstract][Full Text] [Related]
14. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Klein CH; Truxius DC; Vogel HA; Harizanova J; Murarka S; Martín-Gago P; Bastiaens PIH Int J Cancer; 2019 Feb; 144(4):767-776. PubMed ID: 30194764 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel PDEδ interacting proteins. Küchler P; Zimmermann G; Winzker M; Janning P; Waldmann H; Ziegler S Bioorg Med Chem; 2018 May; 26(8):1426-1434. PubMed ID: 28935183 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design. Chen L; Zhuang C; Lu J; Jiang Y; Sheng C J Med Chem; 2018 Mar; 61(6):2604-2610. PubMed ID: 29510040 [TBL] [Abstract][Full Text] [Related]
17. Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of Armijo ME; Escalona E; Peña D; Farias A; Morin V; Baumann M; Klebl BM; Pincheira R; Castro AF Front Pharmacol; 2022; 13():912688. PubMed ID: 35814251 [TBL] [Abstract][Full Text] [Related]
18. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site. Murarka S; Martín-Gago P; Schultz-Fademrecht C; Al Saabi A; Baumann M; Fansa EK; Ismail S; Nussbaumer P; Wittinghofer A; Waldmann H Chemistry; 2017 May; 23(25):6083-6093. PubMed ID: 27809361 [TBL] [Abstract][Full Text] [Related]
19. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Ismail SA; Chen YX; Rusinova A; Chandra A; Bierbaum M; Gremer L; Triola G; Waldmann H; Bastiaens PI; Wittinghofer A Nat Chem Biol; 2011 Oct; 7(12):942-9. PubMed ID: 22002721 [TBL] [Abstract][Full Text] [Related]
20. Dissociation of the K-Ras4B/PDEδ complex upon contact with lipid membranes: membrane delivery instead of extraction. Weise K; Kapoor S; Werkmüller A; Möbitz S; Zimmermann G; Triola G; Waldmann H; Winter R J Am Chem Soc; 2012 Jul; 134(28):11503-10. PubMed ID: 22721555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]